608 related articles for article (PubMed ID: 20883483)
1. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre.
Gajewski JB; Al-Zahrani AA
BJU Int; 2011 Apr; 107(8):1258-64. PubMed ID: 20883483
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up.
Ghazwani YQ; Elkelini MS; Hassouna MM
Neurourol Urodyn; 2011 Sep; 30(7):1271-5. PubMed ID: 21557299
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction.
Peeters K; Sahai A; De Ridder D; Van Der Aa F
BJU Int; 2014 May; 113(5):789-94. PubMed ID: 24238278
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures.
Powell CR; Kreder KJ
J Urol; 2010 Jan; 183(1):173-6. PubMed ID: 19913835
[TBL] [Abstract][Full Text] [Related]
5. Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients.
Peters KM; Jayabalan N; Bui D; Killinger K; Chancellor M; Tyagi P
Low Urin Tract Symptoms; 2015 May; 7(2):77-83. PubMed ID: 26663686
[TBL] [Abstract][Full Text] [Related]
6. [Short-term outcome of sacral neuromodulation on refractory interstitial cystitis/pelvic pain syndrome].
Zhang P; Zhang JZ; Wu LY; Niu HQ; Yang YB; Zhang XD
Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3875-3878. PubMed ID: 28057156
[No Abstract] [Full Text] [Related]
7. Prolonged percutaneous SNM testing does not cause infection-related explanation.
Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
[TBL] [Abstract][Full Text] [Related]
8. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.
Tahseen S
Int Urogynecol J; 2018 Aug; 29(8):1081-1091. PubMed ID: 29302716
[TBL] [Abstract][Full Text] [Related]
9. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland.
Kessler TM; Buchser E; Meyer S; Engeler DS; Al-Khodairy AW; Bersch U; Iselin CE; Roche B; Schmid DM; Schurch B; Zrehen S; Burkhard FC
Eur Urol; 2007 May; 51(5):1357-63. PubMed ID: 17113216
[TBL] [Abstract][Full Text] [Related]
10. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
Hoda MR; Fornara P
Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
[TBL] [Abstract][Full Text] [Related]
11. Sacral neuromodulation for neurogenic non-obstructive urinary retention in incomplete spinal cord patients: a ten-year follow-up single-centre experience.
Lombardi G; Musco S; Celso M; Del Corso F; Del Popolo G
Spinal Cord; 2014 Mar; 52(3):241-5. PubMed ID: 24394604
[TBL] [Abstract][Full Text] [Related]
12. [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic].
Otto W; Nowrotek A; Burger M; Wieland WF; Rößler W; Denzinger S
Aktuelle Urol; 2012 May; 43(3):162-6. PubMed ID: 22639025
[TBL] [Abstract][Full Text] [Related]
13. Prolonged sacral neuromodulation testing using permanent leads: a more reliable patient selection method?
Kessler TM; Madersbacher H; Kiss G
Eur Urol; 2005 May; 47(5):660-5. PubMed ID: 15826759
[TBL] [Abstract][Full Text] [Related]
14. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol.
Rahnama'i MS; Marcelissen T; Apostolidis A; Veit-Rubin N; Schurch B; Cardozo L; Dmochowski R
Neurourol Urodyn; 2018 Jun; 37(S4):S99-S107. PubMed ID: 29363792
[TBL] [Abstract][Full Text] [Related]
16. Sacral neuromodulation in diabetic patients: success and complications in the treatment of voiding dysfunction.
Daniels DH; Powell CR; Braasch MR; Kreder KJ
Neurourol Urodyn; 2010 Apr; 29(4):578-81. PubMed ID: 19760757
[TBL] [Abstract][Full Text] [Related]
17. Sacral neuromodulation in urological indications: the Finnish experience.
Vaarala MH; Tammela TL; Perttilä I; Luukkonen P; Hellström P
Scand J Urol Nephrol; 2011 Feb; 45(1):46-51. PubMed ID: 20961268
[TBL] [Abstract][Full Text] [Related]
18. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study.
Comiter CV
J Urol; 2003 Apr; 169(4):1369-73. PubMed ID: 12629364
[TBL] [Abstract][Full Text] [Related]
19. Sacral neuromodulation treating chronic pelvic pain: a meta-analysis and systematic review of the literature.
Mahran A; Baaklini G; Hassani D; Abolella HA; Safwat AS; Neudecker M; Hijaz AK; Mahajan ST; Siegel SW; El-Nashar SA
Int Urogynecol J; 2019 Jul; 30(7):1023-1035. PubMed ID: 30874835
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of sacral neuromodulation for lower urinary tract dysfunction: A 23-year experience.
Gandhi S; Gajewski JB; Koziarz A; Almutairi S; Ali A; Cox A
Neurourol Urodyn; 2021 Jan; 40(1):461-469. PubMed ID: 33232534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
